Solana欢迎USDe稳定币,Ethena Labs透露支持SOL

币界网Published on 2024-08-08Last updated on 2024-08-08

币界网报道:

USDe稳定币背后的团队Ethena Labs在8月7日与Solana的区块链集成后,今天出现在新闻中。这一战略举措使USDe能够利用Solana的高速和低成本基础设施,显著增强稳定币的能力。

但这还不是全部,因为Solana的原生代币SOL现在将被用作USDe的支持资产,等待治理提案的批准。

根据DeFi项目,

“将SOL纳入支持资产预计将额外释放20亿至30亿美元的未平仓合约。”

可扩展性的提高对稳定币市场至关重要,因为它提供了更多的流动性和稳定性,使USDe成为用户更强大、更可靠的选择。

USDe与Solana的集成也意味着它现在可以在Solana网络上的几个去中心化金融(DeFi)应用程序上使用。这些应用程序包括Kamino finance、Orca、Drift和Jito。用户可以向这些平台提供流动性,或使用USDe作为保证金交易的抵押品。

通过这样做,他们可以获得Ethena Sats,在每个活动结束时可以兑换成ENA代币。此功能为用户提供了更多与DeFi生态系统交互的方式,增强了他们的盈利潜力,并参与了不断增长的DeFi市场。

这对DeFi意味着什么?

例如,Kamino Finance是一个平台,允许用户自动化他们的DeFi策略,使他们更容易优化收益。Orca是一个去中心化的交易所,提供用户友好的界面和高效的交易选项。

相反,Drift提供了一个去中心化的衍生品交易平台,而Jito专注于提供先进的交易工具和分析。

将USDe纳入这些平台将为用户在DeFi空间中使用稳定币提供更强大和多样化的选择。

USDe与Solana的整合标志着Ethena Labs和稳定币市场的一个重要里程碑。通过利用Solana的能力,USDe旨在为用户提供更具可扩展性、高效性和多功能性的稳定币解决方案。

额外的流动性和支持资产将增强USDe的稳定性和实用性,使其成为希望在Solana上使用DeFi应用程序的用户的一个有吸引力的选择。

Trending Cryptos

Related Reads

Stock Price Doubles Within the Year, Plummets 20% After Resumption, Baolai Medical's 'Chip Backdoor Listing' Script Ends

On August 10, 2026, BPL (300246.SZ) resumed trading after a nearly week-long suspension and immediately fell by a 20% limit-down. This plunge was triggered by the termination of a planned controlling stake transfer, dashing earlier market speculation. In January 2026, Zhejiang Quwei Zhihe Partnership entered as a significant shareholder, sparking hopes. Investors speculated that its backer, Weigu Information—a specialized "little giant" company in high-reliability solid-state storage chips—might be seeking a backdoor listing through BPL. This "cross-industry restructuring" expectation fueled a strong rally, with BPL's stock price more than doubling in 2026 prior to the halt. However, the deal was called off on August 7, directly causing the sharp sell-off. Underlying BPL's vulnerability is its fundamentally weak business. The company, a medical device firm, is mired in losses, having reported three consecutive years of net losses totaling over 200 million yuan. Its core hemodialysis business is squeezed by government procurement price cuts, while growth in its patient monitor segment has stalled. Furthermore, BPL faces imminent debt pressure with convertible bonds worth approximately 218 million yuan due in September 2026, and its current stock price is far below the conversion price. The failed control transfer may represent a delayed release of negative news, but BPL's core challenges remain: reversing operational losses and addressing its urgent liquidity crisis.

marsbit2h ago

Stock Price Doubles Within the Year, Plummets 20% After Resumption, Baolai Medical's 'Chip Backdoor Listing' Script Ends

marsbit2h ago

Trading

Spot

Hot Articles

Discussions

Welcome to the HTX Community. Here, you can stay informed about the latest platform developments and gain access to professional market insights. Users' opinions on the price of SOL (SOL) are presented below.

活动图片